Addressing large and
growing unmet needs

89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company’s lead product candidate, pegozafermin (BIO89-100), is a specifically engineered glycoPEGylated analog of FGF21. Pegozafermin is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). 89bio is headquartered in San Francisco with operations in Herzliya, Israel.

Leadership

Rohan Palekar
CEO
Dr. Hank Mansbach
Chief Medical Officer
Quoc Le-Nguyen
Chief Technical Operations Officer and Head of Quality
Ryan Martins
Chief Financial Officer
Melissa Abel
SVP, Commercial Strategy
Yun Bai
VP, Head of CMC
Michael Baldwin
VP, Quality Assurance
Amanda Hill
VP, People & Culture
Shiva Natarajan
SVP, Finance & Principal Accounting Officer
Paul Shin
SVP, R&D Operations

Board of Directors

Dr. Steven Altschuler (Chairman)
Managing Director, Ziff Capital Partners
E. Morrey Atkinson, PhD
Senior Vice President, Vertex Pharmaceuticals
Dr. Greg Grunberg
Managing Director, Longitude Capital
Derek DiRocco, PhD
Partner, RA Capital Management
Dr. Michael Hayden
CM, BC, MBChB, PhD, FRCP(C), FRSC
Kathy LaPorte
Lota Zoth
CPA
Rohan Palekar
CEO